Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Change in Working Capital
Inhibrx Inc
Change in Working Capital Peer Comparison
Competitive Change in Working Capital Analysis
Latest Figures & CAGR of Competitors
Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Change in Working Capital
$15.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
$3.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
38%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$2.2B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
-$422m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$275.3m
|
CAGR 3-Years
-158%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
$105.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Inhibrx Inc's Change in Working Capital?
Change in Working Capital
15.3m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Change in Working Capital amounts to 15.3m USD.
What is Inhibrx Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
29%
Over the last year, the Change in Working Capital growth was 386%. The average annual Change in Working Capital growth rates for Inhibrx Inc have been 7% over the past three years , 29% over the past five years .